May 12, 2020 / 5:15 AM / 23 days ago

BRIEF-Sanofi unveils positive results for its Sarclisa product

May 12 (Reuters) - Sanofi:

* Sarclisa(® )(isatuximab) Phase 3 IKEMA trial meets primary endpoint early in patients with relapsed multiple myeloma

* IKEMA trial results released early based on recommendation of an Independent Data Monitoring Committee

* Addition of Sarclisa significantly reduced the risk of disease progression or death compared to carfilzomib and dexamethasone alone

* Results will be submitted to an upcoming medical meeting and form the basis for regulatory submissions later this year (Reporting by Sudip Kar-Gupta)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below